1. Generics Bulletin
  2. >>Products

Lupin Launches Higher Mirabegron Dose ‘At-Risk’

The 25mg Dose Was Launched Back In April, Also ‘At-Risk’

 
• By Urtė Fultinavičiūtė

Lupin and Zydus have established a two-player market for their generic versions of mirabegron, while patent litigation with originator Astellas continues on.

Person pressing a button which launches a rocket
• Source: Shutterstock

Despite the ongoing litigation with originator Astellas, Lupin decided not to wait around and launch its 50mg generic rival to Myrbetriq (mirabegron).

The launch was hinted at by CEO Vinita Gupta during Lupin’s FY25 Q1 earnings call last month

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.